BiotechTube
Home/Britecyte/Alla Danilkovitch
AD

Alla Danilkovitch

Founder, Chief Scientific Officer

Britecyte

Therapeutic Areas

Metabolic DiseasesOsteoarthritisSoft Tissue ReconstructionAesthetic Medicine

Britecyte Pipeline

DrugIndicationPhase
LiposanaAdipose defects / Soft tissue reconstructionCommercial
LipodermaFacial volume restoration / AestheticsCommercial
Metabolic Diseases ProgramMetabolic syndrome, Diabetes, Fatty Liver DiseasePre-clinical
Osteoarthritis ProgramOsteoarthritisPre-clinical

Leadership Team at Britecyte

ST
Samson Tom
President, CEO, Co-Founder
MS
Molly Saunders
Vice President, Sales and Marketing
PF
Peter Friedli
Chairman, Co-Founder
View full Britecyte profile